• Halozyme expanded its global collaboration with argenx to develop subcutaneous formulations for two additional exclusive targets using ENHANZE.
• Expanded deal lifts argenx’s exclusive access to ENHANZE targets to eight from six.
• Halozyme remains eligible for milestone payments, royalties on net sales of products using ENHANZE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061605PR_NEWS_USPR_____LA64930) on October 06, 2026, and is solely responsible for the information contained therein.